Swiss Consumer Finance Stock News

Temenos (SWX:TEMN) has wrapped up FY 2025 with fourth quarter revenue of US$314.6 million and basic EPS of US$0.63, rounding out a trailing twelve month picture that includes revenue of about US$1.1 billion and EPS of US$4.06. Over the past six quarters, revenue has moved between US$232.2 million and US$318.9 million while quarterly EPS ranged from US$0.41 to US$2.34, giving you a clear view of how top line and per share earnings have tracked together through the latest cycle. With a trailing...

Logitech International highlighted steady demand for high end peripherals and enterprise video collaboration products, even as gaming demand differs by region. Management pointed to stronger gaming activity in China alongside softer trends in North America, underscoring mixed regional consumer patterns. The company outlined supply chain plans and reiterated a focus on capital deployment, including M&A and a sizeable share repurchase program. For investors watching SWX:LOGN, the latest...

Julius Bär Gruppe (SWX:BAER) has appointed Winfried Daun as Global Head of Brand & Marketing in a newly created leadership role. The company has introduced new model portfolios for UK financial advisers as part of an expanded UK wealth management approach. Julius Bär Gruppe, a Swiss private banking group, focuses on wealth management services for high net worth and ultra high net worth clients. The new marketing appointment and the UK model portfolios arrive as many wealth managers look to...

How OC Oerlikon’s FY 2025 Results Line Up With The Market Narrative OC Oerlikon (SWX:OERL) opened FY 2025 with first half revenue of CHF 786 million and a basic EPS loss of CHF 0.14, highlighting that profitability remains under pressure even as discontinued operations contributed CHF 16 million. The company has seen revenue move from CHF 835 million in the first half of 2024 to CHF 1,206 million in the second half of 2024, while EPS shifted from CHF 0.06 to CHF 0.09 over the same periods,...

PSP Swiss Property (SWX:PSPN) has put out its FY 2025 numbers with fourth quarter revenue of CHF 99.5m and basic EPS of CHF 3.25, while the trailing twelve months show revenue of CHF 362.2m and basic EPS of CHF 8.91 alongside year on year earnings growth of 8.9%. Over recent periods, the company has seen quarterly revenue move from CHF 88.6m and EPS of CHF 3.25 in Q4 2024 to CHF 99.5m and EPS of CHF 3.25 in Q4 2025. This is set against a five year EPS trend that declined about 7% a year,...

Alcon FY 2025 earnings: revenue push with mixed profit signals Alcon (SWX:ALC) has wrapped up FY 2025 with fourth quarter revenue of US$2.7 billion and basic EPS of US$0.44, alongside trailing 12 month revenue of US$10.4 billion and basic EPS of US$1.99 that frame the latest print against a fuller year of performance. The company has seen quarterly revenue move from US$2.5 billion in Q4 2024 to US$2.7 billion in Q4 2025, while basic EPS shifted from US$0.57 to US$0.44 over the same period...

Dormakaba Holding (SWX:DOKA) has kicked off H1 2026 with revenue of CHF1.4b and basic EPS of CHF0.97, alongside net income of CHF40.5m, as investors weigh those figures against a year that saw earnings grow 30% and net profit margin reach 3.1%. Over the last three reported half years, revenue has moved from CHF1.4b in H1 2025 to CHF1.4b in H2 2025 and then to CHF1.4b in H1 2026. Over the same period, basic EPS has shifted from CHF1.20 to CHF1.14 and now CHF0.97, providing a clear view of how...

Roche Holding (SWX:ROG) reported that the US FDA accepted its New Drug Application for giredestrant, an oral therapy candidate for advanced ER-positive, ESR1-mutated breast cancer. The company also released positive phase III MAJESTY trial results for Gazyva/Gazyvaro in primary membranous nephropathy. Both developments relate to conditions with high unmet medical need and could influence future treatment options in oncology and nephrology. Roche, known for its focus on oncology and...

Holcim earnings in focus Holcim (SWX:HOLN) heads into its 27 February 2026 earnings release with investors watching closely for margin guidance, cement pricing updates, regional demand commentary, and any signals around near term stock volatility. See our latest analysis for Holcim. Holcim’s 1 day share price return of 1.12% and 7 day share price return of 4.77% contrast with a 30 day share price decline of 4.74%. At the same time, a 1 year total shareholder return of 60.63% and 3 year total...

SoftwareOne Holding (SWX:SWON) is in focus after announcing it has become one of the first global authorized Google Cloud distributors. The company will extend access to Google Cloud products across 10 initial launch markets. See our latest analysis for SoftwareOne Holding. The announcement comes after a tough stretch for the stock, with a 30 day share price return of a 20.76% decline and a year to date share price return of a 26.16% decline, while the 1 year total shareholder return of 8.43%...

Nestlé (SWX:NESN) is in advanced talks to sell its ice cream business as part of a CEO led turnaround plan. The company has also begun a sale process for its waters and drinks division, pointing to a potential exit from sizeable parts of its portfolio. These moves follow pressure on profits linked to baby formula recalls and increasing demands from shareholders for change. Nestlé is one of the largest global consumer packaged food companies, with brands across coffee, pet care,...

Siegfried Holding (SWX:SFZN) has released its full year 2025 results, reporting CHF 1,327.83 million in sales and CHF 168.66 million in net income, along with management changes and updates on recent acquisitions. See our latest analysis for Siegfried Holding. The latest CHF80.7 share price leaves Siegfried Holding with a 90 day share price return of 12.4%, while the 1 year total shareholder return of 16.8% decline contrasts with a 24.2% gain over three years. This suggests that longer term...

Recently, ABB has seen elevated trading activity in pre-market sessions, supported by ongoing industrial demand and strong spending in robotics and electrification solutions. An interesting angle is that third-party AI-driven models are flagging medium-term growth opportunities for ABB, even as some valuation concerns remain. We’ll now examine how this renewed confidence in robotics and automation demand fits into, and potentially reshapes, ABB’s existing investment narrative. The future of...

Temenos (SWX:TEMN) is back in focus after reporting fourth quarter and full year 2025 results, with softer quarterly earnings but higher full year revenue and net income, prompting investors to reassess the stock. See our latest analysis for Temenos. Temenos shares trade at CHF64.2, with a 1 day share price return of 0.94% and a 7 day share price return of 1.82%. The 30 day share price return shows a 13.36% decline and the year to date share price return shows a 21.23% decline, while the 5...

If you are wondering whether Amrize is priced fairly or if there could be value on the table, this article will walk through what the current share price might be telling you. Amrize shares last closed at CHF 50.14, with returns of 13.7% over the past week, 16.7% over the past month and 12.7% year to date, which may have changed how investors view its potential and its risks. Recent attention around Amrize has prompted fresh interest in how the company is being valued, with investors looking...

Sika (SWX:SIKA) has agreed to acquire Turkey based adhesives and sealants manufacturer Akkim. The deal is part of Sika’s Strategy 2028 to expand its adhesives and sealants business globally. The planned transaction increases Sika’s production footprint and presence in high growth markets. Sika focuses on specialty chemicals for construction and industrial applications, and adhesives and sealants are a core part of that offering. By adding Akkim’s product range and manufacturing base in...

Belimo Holding (SWX:BEAN) has released its FY 2025 figures with second half revenue of CHF 559.3 million, basic EPS of CHF 6.54 and net income of CHF 80.4 million, while the trailing twelve month revenue sits at CHF 1.1 billion with EPS of CHF 14.77 and net income of CHF 181.6 million. The company has seen revenue move from CHF 470.3 million and EPS of CHF 5.65 in the second half of 2024 to CHF 561.5 million and EPS of CHF 8.23 in the first half of 2025, setting up this latest CHF 559.3...

If you are wondering whether Partners Group Holding is currently offering fair value or a potential opportunity, looking closely at its valuation can help put the recent share price in context. The stock closed at CHF 852.60, with returns of 9.6% decline over 7 days, 20.2% decline over 30 days, 17.2% decline year to date, 33.2% decline over 1 year, 7% return over 3 years and 11.2% decline over 5 years. These moves may have changed how the market views its risk and potential. Recent coverage...

Novartis has agreed to divest its majority stake in Novartis India Ltd. to a private equity led consortium, reshaping its footprint in the Indian market. • The company reported new late stage clinical results for remibrutinib in chronic urticaria and plans to present further data at a major allergy and immunology conference. These moves highlight a shift in focus toward its core medicines portfolio and immunology pipeline activity. For investors tracking SWX:NOVN, these updates come with...

PSP Swiss Property recently reported its 2025 results, with net income rising on property revaluations, a portfolio of about CHF 10.10 billion, and a proposed dividend increase to CHF 3.95 per share. An interesting angle is that the higher dividend comes even as underlying earnings softened, underscoring management’s reliance on revaluation gains and confidence in funding major redevelopment projects from a strong balance sheet. We’ll now examine how the higher dividend proposal, underpinned...

FDA filing for breast cancer drug puts Roche Holding (SWX:ROG) in focus Roche Holding (SWX:ROG) is back on investors’ radar after the U.S. FDA accepted its New Drug Application for giredestrant in ER positive, HER2 negative, ESR1 mutated advanced breast cancer. The filing, supported by phase III evERA Breast Cancer data, comes alongside positive readouts for Gazyva in kidney disease and constructive industry views on next generation sequencing and genetic testing, areas where Roche is an...

If you are wondering whether Nestlé shares still justify their price, you are not alone; the stock often attracts investors who care about what they are actually paying for each franc of underlying business. Nestlé shares last closed at CHF81.40, with returns of 1.5% over 7 days, 12.3% over 30 days, 6.5% year to date, and a 3.9% decline over 1 year, 17.8% decline over 3 years, and 3.3% decline over 5 years, hinting at changing views on its growth and risk profile. Recent headlines around...

Zug Estates Holding (SWX:ZUGN) drew fresh investor attention after reporting full year 2025 results, with revenue of CHF 91.5 million, net income of CHF 85.18 million, and an announced annual dividend of CHF 49 per share. See our latest analysis for Zug Estates Holding. The share price has climbed to CHF 2,400, with an 8.11% 1 month share price return and 11.63% 3 month share price return. The 1 year total shareholder return of 19.75% suggests momentum has been building over a longer...

If you are wondering whether Cosmo Pharmaceuticals at CHF116.20 is priced attractively or already baking in a lot of optimism, this article walks through what the numbers say about its value. The stock shows returns of 0.5% over 7 days, 1.8% over 30 days, 10.2% year to date, 76.5% over 1 year, 105.4% over 3 years and 53.4% over 5 years, which may prompt questions about how much of this performance is supported by fundamentals. Recent coverage has focused on Cosmo Pharmaceuticals' position...